肝硬化患者失代偿期病情的控制和并发症的预防

钟升; 宋鑫月; 牛俊奇

doi:10.3969/j.issn.1001-5256.2016.06.002

肝硬化患者失代偿期病情的控制和并发症的预防

DOI: 10.3969/j.issn.1001-5256.2016.06.002

吉林大学第一附属医院肝胆胰内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2388
- HTML全文浏览量: 11
- PDF下载量: 690
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Control of patients' condition and prevention of complications in patients with decompensated liver cirrhosis

摘要

摘要: 肝硬化是我国消化系统常见疾病,也是后果严重的疾病。引起肝硬化的原因复杂多样,临床上把肝硬化分为代偿期和失代偿期,预防和控制肝硬化向失代偿方向发展对早期肝硬化患者具有重要意义。综述了肝硬化患者肝功能失代偿预防的几个主要方面。
- 肝硬化 /
- 综合预防 /
- 述评
Abstract: Liver cirrhosis is a common digestive disease in China with serious consequences in clinical practice.There are many causes of liver cirrhosis,and in clinical practice,liver cirrhosis is classified into compensated and decompensated liver cirrhosis.Prevention and control of the progression of liver cirrhosis to decompensated liver cirrhosis is of great significance for patients in the early stage of liver cirrhosis.This article reviews the major aspects in the prevention of decompensated liver cirrhosis.
- liver cirrhosis /
- universal precautions /
- editorial

HTML全文

参考文献(14)

[1]SCHUPPAN D,AFDHAL NH.Liver cirrhosis[J].Lancet,2008,371(9615):838-851.

[2]CHEN Y,TIAN H,HUANG XL.Clinical analysis of non-variceal upper gastrointestinal bleeding in cirrhotic patients[J].J Sun Yat-Sen Univ:Medical Sciences,2014,35(2):278-283.(in Chinese)陈妤,田虹,黄晓丽,等.肝硬化合并非静脉曲张性上消化道出血临床分析[J].中山大学学报:医学科学版,2014,35(2):278-283.

[3]DING XL.Clinical features of liver cirrhosis of different causes:a comparative analysis[D].Yinchuan:Ningxia Med Univ,2013.(in Chinese)丁晓玲.不同病因肝硬化临床特征对比分析[D].银川:宁夏医科大学,2013.

[4]LIU JJ,LI N,ZHI H,et al.Current clinical perspectives and implications of cirrhotic ascites in China[J].J Clin Hepatol,2012,28(9):701-703.(in Chinese)刘建军,李楠,智红,等.对肝硬化腹水诊治中若干问题的认识与思考[J].临床肝胆病杂志,2012,28(9):701-703.

[5]JULIUSSON G,IMAM M,BJOERNSSON ES,et al.Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis[J].Scand J Gastroenterol,2016,51(6):745-752.

[6]ZHANG JW,SHI YQ,HAN Y.Progress in treatment of liver cirrhosis[J].J Clin Hepatol,2015,31(3):465-468.(in Chinese)张静雯,时永全,韩英.肝硬化的治疗进展[J].临床肝胆病杂志,2015,31(3):465-468.

[7] WANG JY.Internal medicine[M].Beijing:People's Medical Publishing House,2015:552-553.(in Chinese)王吉耀.内科学[M].北京:人民卫生出版社,2015:552-553.

[8]LIANG XE,DAI L,YANG SL,et al.Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection[J].Dig Liver Dis,2016,48(5):512-518.

[9]LI YY.Antiviral therapy for hepatitis B/C virus-related cirrhosis[J].J Clin Hepatol,2014,30(7):596-600.(in Chinese)李瑜元.HBV和HCV相关肝硬化的抗病毒治疗[J].临床肝胆病杂志,2014,30(7):596-600.

[10]JIAO YQ.Prevention and treatment of complications of liver cirrhosis[J].Clin Med,2014,34(9):48-49.(in Chinese)焦月琴.肝硬化并发症的预防和治疗[J].临床医学,2014,34(9):48-49.

[11] SOURIANARAYANANE A,THANDASSERY RB.Renal dysfunction in cirrhosis:pathophysiology,diagnosis,and management[J].Minerva Gastroenterol Dietol,2016,62(2):183-196.

[12]Under the auspices of the Italian Association for the Study of Liver Diseases(AISF)and the Italian Society of Internal Medicine(SI-MI).Hemostatic balance in patients with liver cirrhosis:Report of a consensus conference[J].Dig Liver Dis,2016,48(5):455-467.

[13]VOLK ML.Hospital readmission of patients with cirrhosis:a canary in a coal mine[J].Clin Gastroenterol Hepatol,2016,14(5):760-761.

[14] TREBICKA J,SCHIERWAGEN R.Statins,Rho GTPases and KLF2:new mechanistic insight into liver fibrosis and portal hypertension[J].Gut,2015,64(9):1349-1350.

施引文献

资源附件(0)

访问统计